| 000 | 02865cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031524.0 | ||
| 008 | 160622s2016 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.07.Ph.D.2016.Sa.G | ||
| 100 | 0 | _aSafa Nabil Abdelfattah Mohamed | |
| 245 | 1 | 0 |
_aGSTP1 gene mutation as a risk factor for development of M2 and M4 subtypes of acute myeloid Leukemia / _cSafa Nabil Abdelfattah Mohamed ; Supervised Hoda Ali Sadek , Shadia Hassan Ragab , Mosaad Mahmoud Eegammal |
| 246 | 1 | 5 | _aمن سرطان الدم الميلودى الحاد M4و M2كعامل يعرض لخطر نشئة نوعى GSTP1طفرة جين |
| 260 |
_aCairo : _bSafa Nabil Abdelfattah Mohamed , _c2016 |
||
| 300 |
_a169 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology | ||
| 520 | _aGlutathione S-tansfeases comprise a family of phase II detoxification enzymes involved in the metabolism of many environmental carcinogens, drugs & other xenobiotics. GSTP1 gene (I105V) mutation alters the protein function, diminishing its detoxification ability for certain mutagens and carcinogens which could result in increased DNA damage & an increased risk of leukaemogenesis. In our study we aimed to clarify the relation between GSTP1 gene (I105V) mutation and the risk of M2 & M4-AML. We also studied the relation between GSTP1 genotypes and the clinical presentations, hematological findings and treatment response in AML cases. We analyzed the presence of this mutation in 100 de novo M2 & M4-AML patients and 100 age & sex matched controls, using PCR-based restriction fragment length polymorphism (PCR-RFLP) technique. Our study suggests that individuals with at least one GSTP1 codon 105 Val allele are at a significantly high risk of developing M2 and M4 subtypes of AML. We also found a significant elevation of the valine allele among the M4 cases compared to M2 cases. GSTP1 polymorphism was associated with a higher platelet count and a lower bleeding tendency on clinical basis in M2 and M4-AML patients. Also the GSTP1 mutant genotypes were associated with more induction related mortality and less complete remission rates. Hence the present study suggests that GSTP1 Ile105Val polymorphism might influence M2 and M4-AML development, progression and response to therapy | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAML | |
| 653 | 4 | _aGSTP1 | |
| 653 | 4 | _aMutation | |
| 700 | 0 |
_aHoda Ali Sadek , _eSupervisor |
|
| 700 | 0 |
_aMosaad Mahmoud Elgammal , _eSupervisor |
|
| 700 | 0 |
_aShadia Hassan Ragab , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aEnas _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c57005 _d57005 |
||